Streetbeat News

Analyst Ratings

REGN

Regeneron Pharmaceuticals shares declined following a downgrade by Leerink Partners from Outperform to Market Perform, with a reduced price target from $1175 to $1077.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 1:55 pm

CRWD

JMP Securities analyst Trevor Walsh has reiterated a Market Outperform rating for CrowdStrike Holdings (NASDAQ:CRWD) and maintained a $400 price target.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 1:55 pm

AAPL

AMZN

GOOGL

META

MSFT

Needham analyst Laura Martin reiterated a buy rating on Apple Inc (AAPL) with a $260 price target, highlighting the iPhone's significant contribution to Apple's projected 2025 revenue. The analyst contrasts Apple's strategy with other tech giants like Amazon, Alphabet, Microsoft, and Meta, which are heavily investing in AI without visible revenue upside. Apple's focus on its installed base and share repurchases is seen as a safer investment.

Portfolio Pulse from Anusuya Lahiri

September 24, 2024 | 1:55 pm

ACN

JP Morgan analyst Tien-Tsin Huang maintains an Overweight rating on Accenture (NYSE:ACN) but lowers the price target from $376 to $370.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 1:55 pm

ETSY

Truist Securities has reiterated its Buy rating on Etsy, maintaining a price target of $76. Analyst Youssef Squali continues to show confidence in the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 1:55 pm

REPL

JP Morgan analyst Anupam Rama has maintained an Overweight rating on Replimune Group and raised the price target from $14 to $17.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 1:54 pm

MCK

McKesson's stock is trading lower following a downgrade by Baird from Outperform to Neutral, with a reduced price target from $603 to $531.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 1:52 pm

BNTX

BioNTech shares rise as Morgan Stanley upgrades the stock from Equal-Weight to Overweight, increasing the price target from $93 to $145.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 1:49 pm

REGN

Truist Securities has reiterated its Buy rating for Regeneron Pharmaceuticals, maintaining a price target of $1200.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 1:49 pm

CEG

Barclays analyst Nicholas Campanella maintains an Overweight rating on Constellation Energy and raises the price target from $211 to $280.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 1:47 pm